Endometrial Cancer Recurrence in Patients Taking Metformin

Status Active, not recruiting

Clinical Trial Summary

Given the early literature available and its biological plausibility as an inhibitor of the mammalian target of rapamycin (mTOR) protein, it is hypothesized that women with endometrial cancer who take metformin for non-cancer related reasons have a lower cancer recurrence rate compared to women not taking metformin. The primary goal of this study is to determine whether metformin use is associated with a decrease in the rate of endometrial cancer recurrence. Secondary objectives are to assess whether women with endometrial cancer taking metformin have longer progression free survival and overall survival than those that do not take metformin.

Clinical Trial Description

This is a retrospective chart review study. Medical records are reviewed and data collected through the hospital's electronic medical record (EMR). Participants are women that had definitive treatment for endometrial cancer between 2016-2020 at WellSpan York Hospital Department of Gynecologic Oncology. Participants are identified and their chart reviewed for demographic data of age, race, comorbid conditions, and use of metformin. Possible confounding information is documented, including chemotherapy status, radiotherapy status, cancer and tumor type, grade, and stage, available genetics information, medications at the time of cancer diagnosis, and medication durations. Those patients who had cancer recurrence are identified. Recurrence data including type, time interval, additional treatment are collected. Recurrence is defined as any recurrence validated by clinical, imaging and histological data and can be identified based on the cancer registry. Recurrence rate in participants that took metformin vs. those that did not is calculated. Time to endometrial cancer recurrence is calculated. Progression free survival and overall survival are calculated. Statistical analysis is performed to compare each of these outcomes between participants who took metformin vs. those that did not. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05192850
Study type	Observational
Source	WellSpan Health
Contact
Status	Active, not recruiting
Phase
Start date	December 27, 2021
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03968406` - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers	Phase 1
Active, not recruiting	`NCT03508570` - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	Phase 1
Completed	`NCT00723255` - Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00025467` - Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Active, not recruiting	`NCT03120624` - VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer	Phase 1
Recruiting	`NCT05691504` - Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	Phase 1
Active, not recruiting	`NCT04781088` - Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Phase 2
Completed	`NCT01764789` - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer	N/A
Recruiting	`NCT04469764` - Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer	Phase 2
Terminated	`NCT03924245` - Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers	Phase 1
Completed	`NCT00462826` - VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00096447` - Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00028535` - Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors	Phase 1
Completed	`NCT01652794` - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer	Phase 1
Completed	`NCT01079832` - Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies	Phase 2
Completed	`NCT00095979` - Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00072176` - Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer	Phase 2
Withdrawn	`NCT01943058` - Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer	Phase 2
Completed	`NCT00301964` - Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT01155258` - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	Phase 1